| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 12/12/2001 | EP0662075B1 Prostaglandin analog for treating osteoporosis |
| 12/12/2001 | CN1326459A Heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 12/12/2001 | CN1326458A CRF receptor antagonists and methods relating thereto |
| 12/12/2001 | CN1326457A 4-aminopyrrolopyrimidines as kinase inhibitors |
| 12/12/2001 | CN1326456A 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives |
| 12/12/2001 | CN1326449A Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2, 4-thiazolidinedione |
| 12/12/2001 | CN1326443A Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors |
| 12/12/2001 | CN1326361A Methods for detecting, preventing, and treating renal disorders by modulating, regulating and inhibiting connective tissue growth factor |
| 12/12/2001 | CN1326344A PUFA supplements |
| 12/12/2001 | CN1325723A Chinese medicine for treating diabetes and its preparing process |
| 12/12/2001 | CN1325722A Chinese medicine for treating diabetes and neurovascular lesion of both feet and its preparing process |
| 12/12/2001 | CN1325718A Freeze dried compound queen bee powder |
| 12/12/2001 | CN1325688A Process for preparing high-activity soft capsules of forest frog's oviduct fat |
| 12/12/2001 | CN1325685A Mixtures separated from seeds of syzygium, preparations thereof, and uses as medicines containing them and components therefrom |
| 12/12/2001 | CN1325647A Intestinal flowing liquid containing Taurine |
| 12/12/2001 | CN1325642A Green food able to regulate human cytometaplasia gene |
| 12/12/2001 | CN1075945C High-polymer encapsulated insulin microsome and its preparation method and use |
| 12/11/2001 | US6329545 Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus |
| 12/11/2001 | US6329526 Cycloalkyl substituted imidazoles |
| 12/11/2001 | US6329520 Used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining doses of therapeutic agents that occupy many receptors |
| 12/11/2001 | US6329511 Humanized mouse af2 immunoglobulin having specific amino acid sequences; treatment of autoimmune diseases |
| 12/11/2001 | US6329415 Aromatic heterocyclic compounds as antiinflammatory agents |
| 12/11/2001 | US6329408 Hypocholesterolemic agents; optically pure |
| 12/11/2001 | US6329405 As ileal bile acid transporter inhibitor, for therapy of hyperlipemia |
| 12/11/2001 | US6329404 Pharmaceutical composition |
| 12/11/2001 | US6329397 Hydroxy pipecolate hydroxamic acid derivatives |
| 12/11/2001 | US6329385 Antiinflammatory agents, antiarthritic agents, viral diseases and gastrointestinal disorders |
| 12/11/2001 | US6329362 Modulation cell adhesion the compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders. |
| 12/11/2001 | US6329361 Hypoglycemic agents and stabilization |
| 12/11/2001 | US6329354 Administering bone active phosphonate, administering estrogen hormone |
| 12/11/2001 | US6329344 Urea derivative of alkylene dioxyfuran ethers |
| 12/11/2001 | US6329341 Method of treating septic shock |
| 12/11/2001 | US6329336 Glue and crosslinking agent using albumin |
| 12/11/2001 | US6329159 An antibody or antigen binding fragment which binds mammalian chemokine receptor and inhibits the binding of ligand to the receptor; therapy and diagnosis of inflammatory disease associated with mucosal tissues |
| 12/11/2001 | US6329000 Extract of pine needle and the use thereof |
| 12/11/2001 | US6328998 Artherosclerosis, cardiovascular, anticoagulant, antiischemic |
| 12/11/2001 | US6328995 Stable vitamin and/or carotenoid products in powder form and process for their production |
| 12/11/2001 | US6328964 Method to treat multiple sclerosis with GP39-specific antibodies |
| 12/11/2001 | US6328958 Deleted adenovirus vectors and methods of making and administering the same |
| 12/06/2001 | WO2001092892A2 Methods to identify compounds that modulate rage |
| 12/06/2001 | WO2001092891A2 Regulating lipid levels via the zmax1 or hbm gene |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092485A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE |
| 12/06/2001 | WO2001092479A2 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | WO2001092334A1 Glucose dependent release of insulin from glucose sensing insulin derivatives |
| 12/06/2001 | WO2001092333A2 Use of adnf for enhancing learning and memory |
| 12/06/2001 | WO2001092308A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092241A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors |
| 12/06/2001 | WO2001092239A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | WO2001092224A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092210A1 Compounds for modulating the rage receptor |
| 12/06/2001 | WO2001092204A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 12/06/2001 | WO2001092201A1 Substituted phenylpropionic acid derivatives |
| 12/06/2001 | WO2001091803A2 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091762A1 Zinc-supplementary compositions for oral administration |
| 12/06/2001 | WO2001091754A1 Protein kinase inhibitors |
| 12/06/2001 | WO2001091752A1 Melanocortin receptor agonists |
| 12/06/2001 | WO2001091744A1 Methods of treating androgen deficiency in men using selective antiestrogens |
| 12/06/2001 | WO2001091736A2 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| 12/06/2001 | WO2001091696A2 Use of biguanide derivatives for making a medicine having a wound healing effect |
| 12/06/2001 | WO2001091682A1 Composition and applicator for topical substance delivery |
| 12/06/2001 | WO2001091633A1 A formula to manipulate blood glucose via the calculated ingestion of carbohydrate |
| 12/06/2001 | WO2001091587A2 Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain |
| 12/06/2001 | WO2001051474A3 Polypharmacophoric agents |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001040348A3 Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
| 12/06/2001 | WO2001032031A3 Cholesterol reducing sterol compositions, preparation and method of use |
| 12/06/2001 | WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001010847A8 Novel integrin receptor antagonists |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | WO2000071101A3 Methods and compounds for inhibiting amyloid deposits |
| 12/06/2001 | US20010049446 C-C9-Heteroaryl, linked via C or N, substituted or unsubstitued by 1,3-substituents, substituted benzoylguanidine derivatives useful for treating ischemia, cardiac infarct, angina pectoris, and storke etc. |
| 12/06/2001 | US20010049445 Process for the preparation of thiazolidinedione derivatives |
| 12/06/2001 | US20010049385 Treating obesity; suppressing appetite; treating type 2 diabetes; treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. |
| 12/06/2001 | US20010049382 Or nicotinic acid esters |
| 12/06/2001 | US20010049370 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
| 12/06/2001 | US20010049352 Hydrolyzed whey protein; a carbohydrate source; and a lipid source including a mixture of medium and long chain triglycerides; caloric density of at least 1.4 kcal/mL; ratio of non-protein calories per gram nitrogen of at least 90:1. |
| 12/06/2001 | US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048952 Mixture of aloe vera, collagen, chromium compounds and linoleic acid |
| 12/06/2001 | US20010048948 Intestine health; immunology; mixture containing whey |
| 12/06/2001 | US20010048946 Drug in water soluble polymer matrix |
| 12/06/2001 | US20010048915 Decreased endogenous nitric oxide activation |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | CA2599562A1 Compounds for modulating the rage receptor |
| 12/06/2001 | CA2415470A1 Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain |
| 12/06/2001 | CA2410912A1 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410735A1 Use of adnf for enhancing learning and memory |
| 12/06/2001 | CA2410734A1 Dnas encoding mammalian histamine receptor of the h4 subtype |
| 12/06/2001 | CA2410684A1 Method to determine the differentiation potential of a target cell |